My ePortfolio Register   

ASH 2017 /
Venetoclax plus rituximab for patients with relapsed / refractory CLL

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.17
Views: 1541

Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Seymour speaks with ecancer at the 2017 ASH annual meeting about the randomized phase 3 MURANO study, looking into the use of venetoclax plus rituximab versus bendamustine plus rituximab for patients with relapsed / refractory CLL. The primary endpoint was investigator-assessed progression free survival.

He highlighted that the primary analysis of MURANO shows a profound improvement in progression free survival vs standard bendamustine plus rituximab chemoimmunotherapy, with consistent effects in all-risk subsets.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence